About APiD

Purposes and Activity Policies

Through exchanging opinions on medical needs and developmental trends in the area of infectious diseases, APiD aims to consider future strategic approaches in the area and promote further collaboration among academia, industry and government.
AMED, academic societies (The Japanese Association for Infectious Diseases and Japanese Society of Chemotherapy), and related pharmaceutical companies (The Japan Pharmaceutical Manufacturers Association, JPMA) are major members of APiD.

APiD will be kept as a closed small group consisting of a limited number of representatives recommended by each stakeholder (AMED, related academic societies, JPMA). Additional external experts will be invited as necessary, for the time being.

The recommendations summarized by APiD will be used for the following activities:

Exchange opinions widely from the perspective of drug discovery on the urgent issues of infectious diseases such as AMR
Reflect in AMED activities including strategically select topics for Drug Discovery Support Network, out-licensing to pharmaceutical companies, and planning an open call for research in the same area
Support individual research by academic societies and promote public awareness through adapting the research topics in programs of academic congresses and annual meetings
Develop drug discovery & development strategies, discuss pipelines, explore possibilities of collaboration with academia at each pharmaceutical companies

APiD Member

President of The Japanese Association for Infectious Diseases	Hiroshi Yotsuyanagi The University of Tokyo
President of Japanese Society of Chemotherapy, President of the Japanese Society for Clinical Microbiology	Tetsuya Matsumoto International University of Health and Welfare
7 Academic Society and the Drug Discovery Promotion Review Committee	Kazuhiro Tateda Toho University
The Japan Pharmaceutical Manufacturers Association	Kazuki Hoshino Daiichi Sankyo Co., Ltd.
The Japan Pharmaceutical Manufacturers Association	Yoshinori Yamano SHIONOGI & Co., Ltd.
The Japan Pharmaceutical Manufacturers Association	Yoshisaburo Takahashi Meiji Seika Pharma Co., Ltd.
Japan Agency for Medical Research and Development	AMR participants AMED

AMR Surveillance Committee (Data Sharing)

The committee will discuss specific goals and activities on “Data Sharing” of AMR and “Strain Bank.” In particular, the committee aims at make a viable plans by hearing the opinions at practical level and discussing what can be done by industry, academia, and government.

Drug discovery Support Committee

The results obtained from this committee will be utilized to 1) continuous discovery of drug discovery seeds related to infectious diseases, 2) the right way of AMED support and industry-academia-government collaboration, 3) out-licensing strategies for AMED-supported themes, and 4) research planning related to drug discovery for infectious diseases.